TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tango Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$23.53+1.49 (+6.76%)
Close on Oct 19, 2026
- Market cap
- $3.53B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-178.4%+503.4 pts over 5 years
Net margin
-162.9%+516.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +48.3% | +35.9% | +52.1% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -223.5% | -37.2% | |
| Return on assets | – | – | -28.4% | |
| Current ratio | – | 4.73 | 16.32 | |
| Capex to revenue | – | 14.4% | 1.7% | |
| Diluted shares | – | 32M | 116M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Tango Therapeutics generated $556.98M from operations and spent $12.86M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$556.98M
Used
$12.86M
Capital expenditure$12.86M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-162.9%
×Asset turnover0.17×
×Equity multiplier1.31×
=Return on equity, FY2025-37.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -162.9% | 0.17× | 1.31× | -37.2% |
| FY2024 | -309.7% | 0.12× | 1.59× | -57.6% |
| FY2023 | -278.5% | 0.09× | 1.67× | -40.5% |
| FY2022 | -435.1% | 0.05× | 1.58× | -36.4% |
| FY2021 | -157.2% | 0.10× | 1.85× | -30.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$101.59M
- Cash generatingOperating cash flow above zero-$138.89M
- Return on assets improvedROA up on the prior year-32.4% → -32.1%
- Earnings backed by cashOperating cash flow above net income-$138.89M vs -$101.59M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.98 → 16.32
- No dilutionShare count did not rise109M → 116M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.10 → 0.20